Study of a New Drug for Moderate-to-Severe Eczema
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This trial tests a new medication for people with moderate-to-severe eczema. It aims to see if the treatment is safe and effective for reducing symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have atopic dermatitis (eczema).
- Your eczema must be moderate to severe and currently active.
- You must not have any severe or uncontrolled medical conditions.
- You must not be taking any medications that are not allowed for this trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two new study medicines (PF-07275315 and PF-07264660) for people with moderate to severe eczema that hasn't responded well to other treatments, including biologics. The goal is to see if these medicines can help reduce itching and clear the skin.
This trial tests a new drug called IBI3002 in people with moderate-to-severe atopic dermatitis (eczema) to see if it is safe and tolerable. It may help reduce skin inflammation and itching.
This study tests an experimental treatment for people with moderate to severe eczema that has lasted at least a year. It aims to see if the new medicine can help control symptoms better than current options.
This trial tests a study drug (PF-08049820) for people with moderate to severe eczema who haven't found a suitable prescription treatment. It aims to see if the drug can improve skin symptoms and itching.
This trial tests a new injectable drug called SKB575 for people with moderate to severe atopic dermatitis (eczema). It aims to see how safe and effective the drug is, especially for those who haven't had success with strong creams or pills.
This trial tests an experimental drug called EC-18 (a pill) for people with moderate to severe eczema that hasn't been controlled well with creams. It aims to see if different doses of the drug can safely reduce itching and skin rash.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.